Loring Wolcott & Coolidge Fiduciary Advisors’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$76.3K Sell
975
-6,600
-87% -$532K ﹤0.01% 405
2026
Q1
$661K Hold
7,575
0.01% 207
2025
Q4
$763K Hold
7,575
0.01% 196
2025
Q3
$714K Buy
7,575
+6,590
+669% +$606K 0.01% 202
2025
Q2
$85.9K Hold
985
﹤0.01% 357
2025
Q1
$82.5K Hold
985
﹤0.01% 349
2024
Q4
$91.1K Hold
985
﹤0.01% 354
2024
Q3
$89.6K Sell
985
-55
-5% -$4.63K ﹤0.01% 346
2024
Q2
$81.2K Sell
1,040
-16
-2% -$1.31K ﹤0.01% 354
2024
Q1
$85.1K Sell
1,056
-510
-33% -$43.5K ﹤0.01% 348
2023
Q4
$137K Sell
1,566
-110
-7% -$8.38K ﹤0.01% 315
2023
Q3
$121K Sell
1,676
-400
-19% -$33.5K ﹤0.01% 333
2023
Q2
$183K Sell
2,076
-301
-13% -$25.9K ﹤0.01% 302
2023
Q1
$192K Sell
2,377
-2,075
-47% -$169K ﹤0.01% 282
2022
Q4
$346K Sell
4,452
-2,503
-36% -$203K ﹤0.01% 231
2022
Q3
$562K Sell
6,955
-542
-7% -$48.7K 0.01% 190
2022
Q2
$673K Sell
7,497
-1,285
-15% -$130K 0.01% 183
2022
Q1
$974K Sell
8,782
-1,945
-18% -$205K 0.01% 163
2021
Q4
$1.11M Buy
10,727
+231
+2% +$26.7K 0.01% 165
2021
Q3
$1.32M Sell
10,496
-87
-0.8% -$11.3K 0.01% 147
2021
Q2
$1.31M Buy
10,583
+6,203
+142% +$779K 0.01% 153
2021
Q1
$517K Buy
4,380
+1,370
+46% +$161K 0.01% 209
2020
Q4
$353K Buy
3,010
+210
+8% +$23.1K ﹤0.01% 235
2020
Q3
$291K Hold
2,800
﹤0.01% 236
2020
Q2
$257K Sell
2,800
-600
-18% -$57.5K ﹤0.01% 232
2020
Q1
$307K Sell
3,400
-2,146
-39% -$228K 0.01% 208
2019
Q4
$629K Sell
5,546
-755
-12% -$82.8K 0.01% 185
2019
Q3
$684K Buy
6,301
+1,795
+40% +$187K 0.01% 178
2019
Q2
$439K Buy
4,506
+600
+15% +$54.8K 0.01% 203
2019
Q1
$356K Sell
3,906
-7,219
-65% -$646K 0.01% 213
2018
Q4
$1.01M Buy
11,125
+7,540
+210% +$705K 0.02% 147
2018
Q3
$353K Sell
3,585
-337
-9% -$31.2K 0.01% 223
2018
Q2
$336K Sell
3,922
-2,023
-34% -$169K 0.01% 229
2018
Q1
$477K Hold
5,945
0.01% 205
2017
Q4
$480K Buy
5,945
+35
+0.6% +$2.8K 0.01% 203
2017
Q3
$460K Hold
5,910
0.01% 199
2017
Q2
$496K Sell
5,910
-50
-0.8% -$4.22K 0.01% 192
2017
Q1
$480K Sell
5,960
-2,076
-26% -$162K 0.01% 192
2016
Q4
$572K Sell
8,036
-2,463
-23% -$194K 0.01% 183
2016
Q3
$907K Sell
10,499
-1,022
-9% -$89.1K 0.02% 154
2016
Q2
$1M Sell
11,521
-3,658
-24% -$296K 0.02% 151
2016
Q1
$1.14M Buy
15,179
+69
+0.5% +$5.2K 0.03% 142
2015
Q4
$1.16M Sell
15,110
-3,606
-19% -$271K 0.03% 145
2015
Q3
$1.39M Hold
18,716
0.04% 134
2015
Q2
$1.39M Sell
18,716
-5,464
-23% -$417K 0.04% 134
2015
Q1
$1.89M Sell
24,180
-11,098
-31% -$841K 0.05% 116
2014
Q4
$2.55M Sell
35,278
-1,530
-4% -$106K 0.07% 107
2014
Q3
$2.28M Sell
36,808
-1,945
-5% -$124K 0.06% 111
2014
Q2
$2.47M Sell
38,753
-23,527
-38% -$1.43M 0.07% 107
2014
Q1
$3.83M Sell
62,280
-23,597
-27% -$1.37M 0.1% 96
2013
Q4
$4.93M Sell
85,877
-18,061
-17% -$1.02M 0.14% 92
2013
Q3
$5.54M Sell
103,938
-62,473
-38% -$3.36M 0.17% 87
2013
Q2
$8.56M Buy
+166,411
New +$8.23M 0.27% 69

Other funds holding MDT

Loring Wolcott & Coolidge Fiduciary Advisors's MDT Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors reduced its Medtronic (MDT) stake by 87% in Q2 2026, selling an estimated $532K and leaving 975 shares worth $76.3K. The position accounts for ﹤0.01% of the portfolio, ranked #405.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.56M in Q2 2013. 1,329 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 975 shares of Medtronic worth $76.3K as of Q2 2026.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 6,600 Medtronic shares in Q2 2026, an estimated $532K.
  • Medtronic made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #405 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Medtronic position peaked at $8.56M in Q2 2013.
  • 1,329 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.